Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis

BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitor and pioglitazone combination therapy have been widely used for patients with inadequate glycemic control on monotherapy. This meta-analysis assessed the efficacy and safety of this combination therapy in patients with type 2 diabetes mellitus (T2D...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ben, Sun, Yan, Sang, Yiquan, Liu, Xuekui, Liang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257459/
https://www.ncbi.nlm.nih.gov/pubmed/30431561
http://dx.doi.org/10.1097/MD.0000000000012633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257459/
https://www.ncbi.nlm.nih.gov/pubmed/30431561
http://dx.doi.org/10.1097/MD.0000000000012633

Ejemplares similares